Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
Let’s talk a bit about return potential, and small-cap stocks. The two attributes are related, and frequently offer investors a fine combination of risk-reward ratio to emphasize the former. It’s the basic arithmetic behind finding a solid return potential. A small cap stock, one with a market value lower than $2 billion, will usually feature a relatively low share price – and when share price is low, even a small gain in absolute terms will quickly translate into a high-percentage return. Some
Are you looking for biotech stocks that could shoot higher? Wall Street analysts who cover the stocks on this list think they could provide some eye-popping gains. Every stock on this list has a consensus price target that's 91% above its present price.
BEDFORD, Mass., October 11, 2021--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the U.S. Food and Drug Administration (FDA) has approved its Supplemental New Drug Application (sNDA) to broaden the DEXTENZA label to add an additional indication for the treatment of ocular itching associated with allergic conjunctivitis. With the appro
BEDFORD, Mass., September 28, 2021--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Karen-Leigh Edwards as Senior Vice President of Technical Operations. Dr. Edwards will join the senior leadership team and be responsible for technical development, manufacturing, quality and supply chain operations.
BEDFORD, Mass., September 22, 2021--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Merilee Raines to the Company’s Board of Directors effective September 20, 2021.
BEDFORD, Mass., September 13, 2021--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported in-market unit sales of DEXTENZA® billable inserts of 6,924 and 9,321 in July and August, respectively, as part of the Company’s corporate presentation at the H.C. Wainwright 23rd Annual Global Investment Conference. August units represent the second hig
BEDFORD, Mass., September 07, 2021--Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held from September 13-15, 2021.
Ocular Therapeutix, Inc. ( NASDAQ:OCUL ) shareholders might be concerned after seeing the share price drop 27% in the...